Issue 1, 2022

ROS activated prodrug for ALDH overexpressed cancer stem cells

Abstract

Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) – consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB – to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

Graphical abstract: ROS activated prodrug for ALDH overexpressed cancer stem cells

Supplementary files

Article information

Article type
Communication
Submitted
08 out 2021
Accepted
25 nov 2021
First published
07 dez 2021

Chem. Commun., 2022,58, 72-75

ROS activated prodrug for ALDH overexpressed cancer stem cells

M. Won, J. H. Kim, M. S. Ji and J. S. Kim, Chem. Commun., 2022, 58, 72 DOI: 10.1039/D1CC05573A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements